Short Course on Structure-Based Drug Design for Epigenetic Targets

[James Prudhomme]

******** PLEASE FORWARD TO YOUR COLLEAGUES********

**************************************************************************
Structure-Based Drug Design for Epigenetic Targets


June 19, 2013 (9:00 am - 12:00 pm)
The Revere Hotel - Boston, MA

<http://www.healthtech.com/sbd> http://www.healthtech.com/sbd
**************************************************************************

Epigenetic processes are the focus of intense interest, and the families of
proteins
that mediate epigenetic signalling are a highly promising source of new drug
targets.
Tackling this emerging field of novel drug targets is not without its
challenges. This
workshop will review the contribution that structural biology has made to
the discovery
of small molecule modulators. Structural information can be invaluable in
determining the
druggability of potential targets, and in enabling more efficient
identification of hit molecules.
Structural information can also guide the design of compounds with improved
affinity for
the target, or selectivity versus other targets. This introductory course
on drug design for
epigenetic targets will focus especially on emerging targets such as
bromodomain (readers),
methyltransferase (writers) and lysine demethylase (erasers).

Instructors:
Johnathan R. Whetstine, Ph.D., Assistant Professor of Medicine, Harvard
Medical School
Philip Fallon, Ph.D., Senior Medicinal Chemist, Domainex Ltd.

This short course will take place prior to the start of CHI/Bio-IT World's
"Structure-Based
Drug Design" conference (June 19-21).

DOWNLOAD PDF BROCHURE:
<http://www.healthtech.com/Conferences_Content.aspx?ekfrm=122075>
http://www.healthtech.com/Conferences_Content.aspx?ekfrm=122075

HOW TO REGISTER:
Web: <https://chidb.com/register/2013/sbd/reg.asp>
https://chidb.com/register/2013/sbd/reg.asp
Call: 781-972-5400
Email: <mailto:r...@healthtech.com> r...@healthtech.com